TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).

By C. Parisi, L. Mahjoubi, A. Gazzah, F. Barlesi. 2023

Subfields: Drug Discovery, Oncology, Pharmacology

Citations in the corpus

• TROP2 expression in head and neck squamous cell carcinoma: association with the tumor immune microenvironment and clinical outcome (2026, unknown): “These fi ndings reinforce previous observations that TROP2 is broadly expressed across epithelial malignancies (27 – 29) and may represent a stable tumor-associated surface antigen suitable for targeted therapeutic strategies (19, 30 – 32).”